Genetics Generation Advancement Corp. Stock
Equities
4160
TW0004160007
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
57.1 TWD | +7.33% | +3.44% | +46.79% |
Sales 2022 | 548M 16.96M | Sales 2023 | 592M 18.34M | Capitalization | 988M 30.6M |
---|---|---|---|---|---|
Net income 2022 | 25M 774K | Net income 2023 | 28M 867K | EV / Sales 2022 | 0.75 x |
Net cash position 2022 | 255M 7.9M | Net cash position 2023 | 266M 8.23M | EV / Sales 2023 | 1.22 x |
P/E ratio 2022 |
26.1
x | P/E ratio 2023 |
34.7
x | Employees | 104 |
Yield 2022 |
1.74% | Yield 2023 |
1.31% | Free-Float | 58.95% |
1 day | +7.33% | ||
1 week | +3.44% | ||
Current month | +14.66% | ||
1 month | +33.10% | ||
3 months | +30.66% | ||
6 months | +35.47% | ||
Current year | +46.79% |
Managers | Title | Age | Since |
---|---|---|---|
Cheng Hsien Tsai
CEO | Chief Executive Officer | - | - |
Tai Sheng Chang
CTO | Chief Tech/Sci/R&D Officer | - | - |
Fang Chun Huang
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Yue Jen Huang
BRD | Director/Board Member | - | 20-06-09 |
Cheng Hsien Tsai
CEO | Chief Executive Officer | - | - |
Wen Cheng Chang
BRD | Director/Board Member | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-05 | 57.1 | +7.33% | 654 895 |
24-05-03 | 53.2 | -2.74% | 635,110 |
24-05-02 | 54.7 | +9.84% | 667,357 |
24-04-30 | 49.8 | -6.04% | 387,996 |
24-04-29 | 53 | -3.99% | 547,143 |
End-of-day quote Taipei Exchange, May 05, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
+46.79% | 41.86M | |
-14.57% | 11.41B | |
+70.48% | 3.81B | |
-28.76% | 2.3B | |
-12.90% | 2.16B | |
+37.48% | 1.19B | |
-2.40% | 760M | |
-14.50% | 506M | |
-34.90% | 444M | |
+13.72% | 339M |
- Stock Market
- Equities
- 4160 Stock